In heterozygous carriers of the mouse reciprocal translocation T(14;15)6Ca, the frequency of nondisjunction involving the minute marker chromosome was 4.4 % in the male and 22.2 % in the female. The fate of gametes with unbalanced genomes derived from normal as well as abnormal meiotic disjunction in T6 heterozygotes was investigated on the basis of chromosome counts at metaphase II and karyotype analyses in early postimplantation embryos produced by backcrossing with chromosomally normal animals. Results obtained indicate that meiotic, gametic, and zygotic selection attributable to specific types of chromosomal imbalances is minimal, if any, by the late blastocyst stage. All zygotes with unbalanced genomes, except those with 20 normal pairs plus the minute marker, however, die off in the latter half of pregnancy. Therefore, the increased incidence of translocation trisomics among progeny of female as compared with male heterozygotes reflects the higher incidence of nondisjunction in primary oocytes than in spermatocytes.

This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.